Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists-Reference-Cited by-同舟云学术

Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists

Published:2015-11-26 Issue:2 Volume:63 Page:644-659
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Trivedi Palak J.¹,Corpechot Christophe²,Pares Albert³,Hirschfield Gideon M.¹

Affiliation:

1. National Institute for Health Research (NIHR), Birmingham Liver Biomedical Research Unit (BRU), and Center for Liver Research; University of Birmingham; Birmingham United Kingdom

2. National Reference Center for Inflammatory Diseases of the Biliary Tract (MIVB), Rare Liver Diseases Health Network (FILFOIE), Saint-Antoine Hospital; Assistance Publique-Hôpitaux de Paris (APHP); Paris France

3. Liver Unit, Hospital Clínic, CIBERehd, IDIBAPS; University of Barcelona; Barcelona Spain

Funder

Stratified Medicine Award from the UK Medical Research Council

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/hep.28128/fullpdf

Reference78 articles.

1. Primary sclerosing cholangitis;Hirschfield;Lancet,2013

2. Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study;Trivedi;Gut,2015